Galectin Therapeutics (GALT) Stock Price, Quote, News & History | Benzinga

Galectin Therapeutics Inc (GALT) Stock Price, Quote, News & History

GALTNASDAQ

Trade with Public

Trade with Public

$3.52

0.010.28%

At close: Aug 18, 5:00 PM EST

$3.52

N/A

After Hours: 4:00 PM EST

Earnings: Q2 2026 Earnings were released on Fri Aug 14th, before the market open

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.47

Close

$3.52

Volume / Avg.

317.94K / 652.78K

Day Range

$3.33 - $3.55

52 Wk Range

2.03 - 7.13

Market Cap

$354.99M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

51

Short Interest

11.3%

Days to Cover

23.63

Recent Galectin Therapeutics Inc News

Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday

Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.

Avi Kapoor

Top 3 Health Care Stocks That May Keep You Up At Night In June

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.

Avi Kapoor

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.

Avi Kapoor

Dow Surges Over 600 Points, Gold Jumps 1.5%

Avi Kapoor

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-15.89M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

15.39M

Free Cash Flow (TTM)

-15.89M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-502.00K

Analyst Trends and Forecast

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$480.68M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-12.25%

Earnings Yield % (FWD)

-8.55%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.38

Company Debt

Total Debt

$137.70M

LT Debt

-

LT Debt Issuance (TTM)

$10.00M

LT Debt Repayment (TTM)

-

Total Cash

$13.27M

Debt to Equity

-

Issuance of Debt (TTM)

$10.00M

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.47

Close

$3.52

Volume / Avg.

317.94K / 652.78K

Day Range

$3.33 - $3.55

52 Wk Range

2.03 - 7.13

Market Cap

$354.99M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

51

Short Interest

11.3%

Days to Cover

23.63

About

Sector

Health Care

Industry

Biotechnology

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (G...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Galectin Therapeutics (GALT) stock?

A

You can purchase shares of Galectin Therapeutics (NASDAQ:GALT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Galectin Therapeutics (GALT) competitors?

A

Other companies in Galectin Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Galectin Therapeutics (GALT) stock?

A

Galectin Therapeutics has a consensus price target of $8.50.

Q

What is the current price for Galectin Therapeutics (GALT)?

A

The stock price for Galectin Therapeutics (NASDAQ: GALT) is $3.52 last updated August 18, 2026 at 4:00 PM EDT.

Q

Does Galectin Therapeutics (GALT) pay a dividend?

A

There are no upcoming dividends for Galectin Therapeutics.

Q

When is Galectin Therapeutics (NASDAQ:GALT) reporting earnings?

A

Galectin Therapeutics does not have any upcoming earnings scheduled.

Q

Is Galectin Therapeutics (GALT) going to split?

A

There is no upcoming split for Galectin Therapeutics.

Q

What sector and industry does Galectin Therapeutics (GALT) operate in?

A

Galectin Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.